ポスター発表H会場

[1-H-P-43] A FIT-FOR-PURPOSE APPROACH TO NONCLINICAL ASSESSMENTS FOR DEVELOPMENT OF FIVE POTENTIAL BIOSIMILARS: RITUXIMAB, TRASTUZUMAB, ADALIMUMAB, INFLIXIMAB AND BEVACIZUMAB

^○1, Yasuhiro Yamato ¹, Sharon L. Ripp ², Anne M. Ryan ³, Susan I. Hurst ², Marjorie Peraza ⁴ (1.Drug Safety Research & Development, Pfizer Japan Inc., 2.Pharmacokinetics, Dynamics & Metabolism, Pfizer, Groton, CT, 3.Drug Safety Research & Development, Pfizer, Groton, CT, 4.Drug Safety Research & Development, Pfizer, Andover, MA)